Cargando…
Targeting purinergic pathway to enhance radiotherapy-induced immunogenic cancer cell death
Emerging evidence has demonstrated that radiotherapy (RT) can not only cause direct damage to cancer cells but also lead to immunogenic cell death (ICD), which involves the activation of host antitumor immune response in tumor immune microenvironment (TIME). RT-induced ICD comprises the release of d...
Autores principales: | Bao, Xuhui, Xie, Liyi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9284706/ https://www.ncbi.nlm.nih.gov/pubmed/35836249 http://dx.doi.org/10.1186/s13046-022-02430-1 |
Ejemplares similares
-
Biomarkers of Radiotherapy-Induced Immunogenic Cell Death
por: Vaes, Rianne D. W., et al.
Publicado: (2021) -
Targeting immunogenic cell death in cancer
por: Ahmed, Asma, et al.
Publicado: (2020) -
Gold Nanoparticles Enhance the Ability of Radiotherapy to Induce Immunogenic Cell Death in Glioblastoma
por: He, Chen, et al.
Publicado: (2023) -
Realizing the Clinical Potential of Immunogenic Cell Death in Cancer Chemotherapy and Radiotherapy
por: Rapoport, Bernardo L., et al.
Publicado: (2019) -
Targeting the purinergic pathway in breast cancer and its therapeutic applications
por: de Araújo, Julia Beatrice, et al.
Publicado: (2021)